672324-91-3

Basic information

• Product Name: 4-(5-Oxazolyl)benzylaMine
• Synonyms: 4-(5-Oxazolyl)benzylaMine;4-(5-oxazolyl)Benzenemethanamine;(4-(Oxazol-5-yl)
• CAS NO: 672324-91-3
• Molecular Formula: C₁₀H₁₀N₂O
• Molecular Weight: 174.1992
• Mol File: 672324-91-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(5-Oxazolyl)benzylaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-Oxazolyl)benzylaMine(672324-91-3)
• EPA Substance Registry System: 4-(5-Oxazolyl)benzylaMine(672324-91-3)

Safety Data

• Hazardous Substances Data: 672324-91-3(Hazardous Substances Data)

Usage

General Description

4-(5-Oxazolyl)benzylamine is an organic chemical compound that belongs to the benzylamine class. It consists of a benzene ring with a 5-oxazolyl group attached to the 4-position of the benzyl group. 4-(5-Oxazolyl)benzylamine is often used in organic synthesis and pharmaceutical research due to its potential applications in the development of various drugs and bioactive molecules. It is also a valuable building block for the synthesis of various heterocyclic compounds and can be used as a precursor in the production of agrochemicals and materials science. Additionally, 4-(5-Oxazolyl)benzylamine has been studied for its potential biological activities, including its potential as a therapeutic agent for various diseases.

Upstream product

• 672324-90-2 4-(5-oxazolyl)-benzamide 
• 101752-05-0 methanol hydrochloride 
• 105-07-7 4-cyanobenzaldehyde 
• 87150-13-8 4-(oxazol-5-yl)benzonitrile 
• 1360616-36-9 tert-butyl 4-(oxazol-5-yl)benzylcarbamate 

Downstream Products

• 1415114-74-7 4-methyl-N-(4-(oxazol-5-yl)benzyl)benzenesulfonamide 
• 1415114-09-8 3-((5-(isoquinolin-6-yl)oxazol-2-yl)amino)phenol 
• 1415114-75-8 N-(2,2-dimethoxyethyl)-4-methyl-N-(4-(oxazol-5-yl)benzyl)benzenesulfonamide 
• 1415114-12-3 N-(3-((5-(isoquinolin-6-yl)oxazol-2-yl)amino)phenyl)-1-phenylmethanesulfonamide 
• 1415114-24-7 N-(3-((5-(isoquinolin-6-yl)oxazol-2-yl)amino)phenyl)methanesulfonamide 
• 1448191-52-3 (2S,4R)-4-(tert-butoxy)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448191-53-4 (2S,4R)-4-(tert-butoxy)-1-(3-ethoxybenzoyl)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448186-44-4 (2S,4R)-1-(3-ethoxybenzoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448186-45-5 (2S,4R)-1-(3-bromobenzoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448186-46-6 C₂₂H₁₉BrClN₃O₄ 
• 1448186-47-7 (2S,4R)-1-(3-cyanobenzoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448186-48-8 C₂₂H₂₁N₃O₅ 
• 1448186-49-9 C₂₃H₂₄N₄O₄ 
• 1448189-85-2 (2S,4R)-tert-butyl 4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR

The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.

Is NMR fragment screening fine-tuned to assess druggability of protein-protein interactions?

Modulation of protein-protein interactions (PPIs) with small molecules has been hampered by a lack of lucid methods capable of reliably identifying high-quality hits. In fragment screening, the low ligand efficiencies associated with PPI target sites pose

Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.